TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.
SynAct Pharma AB announced its participation in the Redeye Autoimmune and Inflammatory Diseases event in Stockholm, where the company’s Chief Business Officer, Mads Bjerregaard, will present updates on their lead compound, resomelagon. This potential first-in-class, non-suppressive immune system modulator is being developed for treating rheumatoid arthritis and acute inflammation due to viral infections, highlighting SynAct’s innovative approach in the field of immunology.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activities, aiding patients in achieving immune balance.
Average Trading Volume: 180,181
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.13B
See more data about SYNACT stock on TipRanks’ Stock Analysis page.